JOHN MCCALL

John McCall specializes in high-level scientific consulting for neuropharmacology and medicinal chemistry, supporting drug discovery and development programs within federal research ecosystems. His core capabilities center on providing expert advisory services to advance therapeutic pipelines, particularly in neuroscience and CNS disorders. He delivers targeted consulting to external oversight committees and internal research teams, bridging preclinical pharmacology with translational drug development. His technical expertise includes pharmacokinetic modeling, target validation, compound optimization, and regulatory-aligned preclinical strategy—skills directly applied to support the National Institute of Neurological Disorders and Stroke’s (NINDS) mission. His differentiation lies in deep domain-specific knowledge of neurotherapeutic mechanisms and the ability to translate complex scientific data into actionable development pathways for early-stage candidates. He maintains a consistent relationship with the Department of Health and Human Services, primarily serving NINDS through specialized scientific advisory roles. His engagements involve supporting structured research networks, guiding external review panels, and providing independent technical oversight to ensure scientific rigor in drug development initiatives. These interactions reflect a pattern of trusted, mission-critical consultation rather than broad administrative or logistical support. His primary NAICS codes—541990 and 541690—reflect his positioning as a niche provider of specialized scientific consulting services outside traditional laboratory or clinical trial functions. He operates at the intersection of pharmaceutical R&D and federal research funding, serving the biopharmaceutical innovation sector with precision-focused expertise in neurotherapeutics and medicinal chemistry. As a sole proprietor under entity structure 2J, John McCall operates as an independent consultant with no formal certifications. Based in Boca Grande, Florida, he maintains a lean, expert-driven presence in the federal science and technology market, offering high-value, focused consulting services to agencies engaged in advanced biomedical research.